European regulators Struggle with Globalisation of Clinical Trials - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European regulators Struggle with Globalisation of Clinical Trials
The globalisation of clinical trials is putting pressure on the European Medicines Agency.


Pharmaceutical Technology Europe
Volume 24, Issue 6

8. I. Hall, "Pharma firms hit back at C4's drugs documentary" (PR Week, 2003). http://www.prweek.com/, accessed 30 April 2012.

9. N. Lakhani "From tragedy to travesty: Drugs tested on survivors of Bhopal" (The Independent, 2011). http://www.independent.co.uk/, accessed 30 April 2012.

10. A. Buncome, "Delhi to examine weak regulation' of clinical trials" (The Independent, 2011). http://www.independent.co.uk/, accessed 30 April 2012.

11. N. Lakhani, "Europe targets drug firms over unethical practices" (The Independent, 2011). http://www.independent.co.uk/. accessed 30 April 2012.

12 Wemos, "The Globalization of Clinical Trials: Testimonies from Human Subjects" (Wemos website, 2010). http://www.wemos.nl/, accessed 30 April 2012.

13 EMA, "Towards a robust global framework for conduct and oversight of clinical trials" (EMA website, 2012). http://www.ema.europa.eu/, accessed 30 April 2012.

14. EMA, "International collaboration on good manufacturing practice inspections expanded" (EMA website, 2012). http://www.ema.europa.eu/, accessed 30 April 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here